Drug intelligence / Profile preview

PTC-2132

Development stage: Preclinical
Lead developer: Ponce Aurora
Modality: Peptides
Administration: Oral

Overview

PTC-2132 is an oral geropeptide candidate developed by Ponce Aurora as part of its MitoXcel™ technology platform. It is designed to target Hischabin 1 and Hischabin 2, which are biological targets involved in the aging process. Classified as a geropeptide, PTC-2132 is intended to promote longevity and cellular health. According to company pipeline information, the candidate is currently in the preclinical stage and has not yet undergone animal testing. It is formulated for oral administration.

Beyond the preview

Go deeper on PTC-2132.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTC-2132.

Explore the full profile